SURPASS-CVOT compared once-weekly tirzepatide with dulaglutide in adults with type 2 diabetes and high cardiovascular risk, showing a 9% relative risk reduction in MACE (HR 0.92, 95% CI 0.83 to 1.01)
It all comes down to one thing: How do I make this system do what I want it to do? By 2010, when he started the Bulletproof blog, hed caffeinated and smart-drugged his way through Wharton Business School, trekked around Tibet and discovered the yak-butter tea that would inspire Bulletproof coffee, and settled on Vancouver Island with his family
Users must pair this medication with a reduced-calorie diet and improved physical activity routine
Indianapolis: Joey Amato: 32
Beyond appetite, abrupt stopping can disrupt metabolic adaptation your body developed during treatment
The rise of telehealth platforms has also made these advancements more accessible